Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in…
In Conversation
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it…
What role does Indonesia play within Quintiles’ Asian operations? Quintiles has been growing dramatically across the South East Asian Region, which comprises Philippines, Singapore, Thailand, Malaysia,…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong…
Pfizer has been one of the earliest believers in the Indonesian market, establishing its presence since 1969. As the number one MNC in Indonesia, how would…
You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago…
